SunTrust Robinson Humphrey Initiates Coverage On Vertex Pharmaceuticals with Buy Rating, Announces $235 Price Target

SunTrust Robinson Humphrey initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy rating and a $235 price target.

Benzinga · 11/12/2019 11:38

SunTrust Robinson Humphrey initiates coverage on Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy rating and a $235 price target.